Sumitomo Pharma Co., Ltd.
SMDPY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4,370,186 | $347,774,953 | $263,911,205 | $256,243,786 |
| - Cash | $260,622 | $20,453,000 | $23,116,000 | $85,393,000 |
| + Debt | $1,779,802 | $309,245,000 | $305,422,000 | $374,423,000 |
| Enterprise Value | $5,889,365 | $636,566,953 | $546,217,205 | $545,273,786 |
| Revenue | $807,747 | $108,002,000 | $105,649,000 | $112,434,000 |
| % Growth | -99.3% | 2.2% | -6% | – |
| Gross Profit | $498,610 | $63,890,000 | $65,978,000 | $70,995,000 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| EBITDA | $584,166 | $26,241,000 | $5,604,000 | $27,471,000 |
| % Margin | 72.3% | 24.3% | 5.3% | 24.4% |
| Net Income | $594,378 | $11,206,000 | $2,415,000 | $53,448,000 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS Diluted | 1.5 | 28.21 | 6.08 | 134.53 |
| % Growth | -94.7% | 364% | -95.5% | – |
| Operating Cash Flow | $125,550 | -$1,329 | $11,009,000 | $939,000 |
| Capital Expenditures | -$7,186 | -$1,474,000 | -$2,375,000 | -$2,057,000 |
| Free Cash Flow | $118,364 | -$1,666,000 | $8,634,000 | -$1,118,000 |